샘플 요청 목록

 카트 문의
시장보고서
상품코드
1908261

계산 병리학 시장 규모, 점유율, 동향 분석 보고서 : 구성요소별, 용도별, 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Computational Pathology Market Size, Share & Trends Analysis Report By Component, By Application, By Technology, By End-use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

계산 병리학 시장 개요

세계의 계산 병리학 시장 규모는 2025년에 7억 2,868만 달러로 추정되며, 2033년에 14억 4,762만 달러에 달할 것으로 예측됩니다.

2026년부터 2033년까지 CAGR 9.21%로 성장할 것으로 예상됩니다. 이러한 성장은 머신러닝과 인공지능(AI) 기술 통합의 발전, 신속한 진단을 위한 고급 솔루션에 대한 수요 증가, 만성질환의 유병률 증가, 고급 솔루션 개발에 주력하는 시장 진입자들의 지원을 받아 의료 부문에 대한 투자 증가에 기인합니다.

암과 같은 만성질환의 유병률 증가가 시장의 주요 촉진요인으로 작용하고 있습니다. 암의 높은 유병률로 인해 병리학자들은 환자별 맞춤 치료를 위해 병리 데이터를 필요로 하고 있습니다. 이에 따라 진단 속도 향상, 진단 정확도 향상, 환자 예후 개선을 위한 치료 권고안을 제공할 수 있는 디지털 병리학이 병리학자들 사이에서 점점 더 선호되고 있습니다. 예를 들어, 2023년 8월 'Journal of Pathology'지에 게재된 연구에 따르면, 조직병리학 이미지를 분석 및 해석하는 딥러닝과 인공지능(AI) 알고리즘은 특히 암 진단 및 예후에 있어 진단 정확도와 효율성을 크게 향상시킬 수 있다고 합니다.

머신러닝과 AI 기술을 병리 워크플로우에 접목하면 진단 프로세스가 크게 변화할 수 있습니다. 예를 들어, 2024년 10월에는 Proscia가 AI 모델 개발을 지원하는 디지털 병리 툴킷을 발표했습니다. 이러한 도구를 통해 생명과학 연구자들은 생검 슬라이드 이미지를 정량적 데이터로 변환하고, 기초 모델을 훈련하고, 바이오마커 발견을 촉진하고, 진단을 개선할 수 있습니다. 이러한 솔루션의 개발로 빠르고 정확한 이미지 분석이 가능해져 병리학자들은 질병 진행을 나타낼 수 있는 패턴을 식별할 수 있게 됩니다. AI는 일상 업무를 자동화함으로써 병리과 의사가 보다 복잡한 진단 과제에 집중할 수 있도록 하여 효율성과 정확성을 향상시킬 수 있습니다. 이러한 변화는 진단의 정확도를 높이고 예측 모델링을 통한 맞춤형 의료의 발전을 지원합니다.

시장에는 중요한 요인에 의해 주도되는 큰 기회가 존재합니다. 인공지능(AI), 머신러닝(ML), 디지털 이미징의 발전은 병리학적 워크플로우를 변화시키고, 조직 슬라이드를 보다 빠르고 정밀하게 분석하여 질병 진단과 예후에 대한 중요한 인사이트를 제공하고 있습니다. 이러한 기술 발전은 암, 심혈관질환과 같은 만성질환의 전 세계 유병률 증가에 따라 신속하고 정확한 진단에 대한 수요 증가에 대응하고 있습니다.

또한, 원격 병리 진단의 보급 확대로 특히 의료 자원이 부족한 지역에서 원격지 전문가 상담이 확대되어 의료 접근성이 개선되고 있습니다. 디지털 헬스 시스템의 통합은 검사실의 효율성을 높이고 일상 업무의 자동화를 촉진하며 병리학자가 복잡한 진단에 집중할 수 있도록 돕습니다. 이를 통해 정확도 향상과 맞춤형 의료의 발전을 촉진합니다. 또한, 의료 제공자 및 업계 관계자들의 AI를 활용한 병리 진단 솔루션 개발에 대한 투자 증가는 혁신과 시장 성장을 촉진하고 있습니다.

자주 묻는 질문

  • 계산 병리학 시장 규모는 어떻게 예측되나요?
  • 계산 병리학 시장의 주요 성장 요인은 무엇인가요?
  • 디지털 병리학의 선호 이유는 무엇인가요?
  • AI와 머신러닝 기술이 병리학에 미치는 영향은 무엇인가요?
  • 원격 병리 진단의 장점은 무엇인가요?
  • 계산 병리학 시장의 주요 기업은 어디인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 계산 병리학 시장 변수, 동향과 범위

  • 시장 역학
  • 사용 사례 연구 인사이트
  • 계산 병리학 시장 분석 툴
    • 산업 분석 - Porter's Five Forces 분석
    • PESTEL 분석
    • 기술 동향 분석

제4장 계산 병리학 시장 : 구성요소별, 추정·동향 분석

  • 구성요소별 시장 점유율(2025년과 2033년)
  • 세계의 계산 병리학 시장 : 구성요소별 전망
  • 소프트웨어
  • 서비스

제5장 계산 병리학 시장 : 용도별, 추정·동향 분석

  • 용도별 시장 점유율(2025년과 2033년)
  • 세계의 계산 병리학 시장 : 용도별 전망
  • 질환 진단
  • Drug Discovery & Development
  • 학술 연구

제6장 계산 병리학 시장 : 기술별, 추정·동향 분석

  • 기술별 시장 점유율(2025년과 2033년)
  • 세계의 계산 병리학 시장 : 기술별 전망
  • 머신러닝(ML)
    • 딥러닝
    • 지도
    • 비지도
    • 기타
  • 자연어 처리(NLP) 모델
  • 컴퓨터 비전
  • 기타

제7장 계산 병리학 시장 : 최종 용도별, 추정·동향 분석

  • 최종 용도별 시장 점유율(2025년과 2033년)
  • 세계의 계산 병리학 시장 : 최종 용도별 전망
  • 병원과 진단 실험실
  • 바이오테크놀러지와 제약 기업
  • 학술·연구기관
  • 기타

제8장 계산 병리학 시장 : 지역별, 추정·동향 분석, 구성요소별, 용도별, 기술별, 최종 용도별

  • 지역별 시장 점유율 분석(2025년과 2033년)
  • 지역별 시장 대시보드
  • 세계 지역별 시장 개요
  • 시장 규모와 예측 동향 분석, 2021-2033년
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제9장 경쟁 구도

  • 주요 시장 진입 기업의 최근 동향과 영향 분석
  • 기업/경쟁 분류
  • 주요 기업의 시장 점유율·포지션 분석(2025년)
  • 기업 개요
    • Leica Biosystems Nussloch GmbH(Danaher의 자회사)
    • Hamamatsu Photonics K.K.
    • Koninklijke Philips N.V.
    • Olympus Corporation
    • F. Hoffmann-La Roche Ltd.
    • Aiforia/Aiforia Technologies PLC
    • Epredia(3DHISTECH Ltd.)
    • Visiopharm A/S
    • Proscia Inc.
    • Mindpeak GmbH
    • Akoya Biosciences, Inc.(Quanterix의 자회사)
    • Paige AI, Inc.
    • CellaVision
    • aetherAI
    • Qritive
    • IBEX(IBEX MEDICAL ANALYTICS)
    • Nucleai, Inc.
KSM 26.01.26

Computational Pathology Market Summary

The global computational pathology market size was estimated at USD 728.68 million in 2025 and is projected to reach USD 1,447.62 million by 2033, growing at a CAGR of 9.21% from 2026 to 2033. The growth is attributed to the rising integration of machine learning and artificial intelligence (AI) technologies, the increasing demand for advanced solutions for faster diagnosis, the rising prevalence of chronic diseases, and increasing investment in healthcare, supported by market players focused on developing advanced solutions.

The growing prevalence of chronic diseases, such as cancer, predominantly drives the market. Owing to the high prevalence of cancer, pathologists require pathology data that can facilitate customizing therapies for patients. Thereby, digital pathology is increasingly being preferred by pathologists, as it accelerates the rate of diagnosis, increases diagnostic accuracy, and provides therapeutic recommendations to improve patient outcomes. For instance, according to a study published in the Journal of Pathology in August 2023, deep learning and artificial intelligence (AI) algorithms to analyze and interpret histopathology images promise substantial improvements in diagnostic accuracy and efficiency, especially for cancer diagnosis and prognosis.

The incorporation of machine learning and AI technologies into pathology workflows significantly transforms the diagnostic process. For instance, in October 2024, Proscia introduced digital pathology toolkits designed to facilitate the development of AI models. These tools enable life science researchers to convert biopsy slide images into quantitative data for training foundation models, improving biomarker discovery, and diagnostics. The development of such solutions enables the rapid and accurate analysis of images, allowing pathologists to identify patterns that may indicate disease progression. By automating routine tasks, AI enables pathologists to focus on more complex diagnostic challenges, thereby improving efficiency and accuracy. This shift enhances diagnostic precision and supports the development of personalized medicine through predictive modeling.

The market holds substantial opportunities driven by significant factors. Advances in artificial intelligence (AI), machine learning (ML), and digital imaging are transforming pathological workflows, enabling faster, more precise analysis of tissue slides and providing critical insights into disease diagnosis and prognosis. This technological progress is addressing the growing demand for rapid, accurate diagnostics, owing to the rising global prevalence of chronic diseases such as cancer and cardiovascular conditions.

Moreover, increasing adoption of telepathology is expanding remote expert consultations and improving healthcare access, especially in underserved regions. Integrating digital health systems enhances laboratory efficiency, automates routine tasks, and allows pathologists to focus on complex diagnostics, fostering greater accuracy and personalized medicine development. Furthermore, rising investments by healthcare providers and industry players in developing AI-powered pathology solutions stimulate innovation and market growth.

Global Computational Pathology Market Report Segmentation

This report forecasts revenue growth and provides, at global, regional, and country levels, an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global computational pathology market report based on components, application, technology, end-use, and region:

  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Software
  • Services
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Disease Diagnosis
  • Drug Discovery & Development
  • Academic Research
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Machine Learning (ML)
    • Deep Learning
    • Supervised
    • Unsupervised
    • Others
  • Natural Language Processing (NLP) Models
  • Computer Vision
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Diagnostic Labs
  • Biotechnology and Pharmaceutical Companies
  • Academic and Research Institutes
  • Other
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional scope
    • 1.1.2. Component
    • 1.1.3. Technology
    • 1.1.4. Application
    • 1.1.5. End Use
  • 1.2. Estimates and forecast timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database.
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Component
    • 2.2.2. Technology
    • 2.2.3. Application
    • 2.2.4. End Use
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Computational Pathology Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
      • 3.1.1.1. Increasing prevalence of chronic diseases
      • 3.1.1.2. Higher cost-efficiency
      • 3.1.1.3. Rapid technological advancements in computational pathology
      • 3.1.1.4. Emergence of Quantitative Continuous Scoring (QCS) in digital pathology
    • 3.1.2. Market restraint analysis
      • 3.1.2.1. High cost of implementing digital and computational pathology solutions
      • 3.1.2.2. Stringent regulatory requirements
    • 3.1.3. Market Opportunity Analysis
    • 3.1.4. Market Challenge Analysis
  • 3.2. Case Study Insights
  • 3.3. Computational Pathology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
    • 3.3.3. Technology Trends Analysis

Chapter 4. Computational Pathology Market: Component Estimates & Trend Analysis

  • 4.1. Component Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Computational Pathology Market by Component Outlook
  • 4.4. Software
    • 4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Services
    • 4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Computational Pathology Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Computational Pathology Market by Application Outlook
  • 5.4. Disease Diagnosis
    • 5.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Drug Discovery & Development
    • 5.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Academic Research
    • 5.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Computational Pathology Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Computational Pathology Market by Technology Outlook
  • 6.4. Machine Learning (ML)
    • 6.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Deep Learning
      • 6.4.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Supervised
      • 6.4.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Unsupervised
      • 6.4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Natural Language Processing (NLP) Models
    • 6.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Computer Vision
    • 6.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Computational Pathology Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2025 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Computational Pathology Market by End Use Outlook
  • 7.4. Hospitals and Diagnostic Labs
    • 7.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Biotechnology and Pharmaceutical Companies
    • 7.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Academic and Research Institutes
    • 7.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Computational Pathology Market: Regional Estimates & Trend Analysis, By Component, By Application, By Technology, By End Use

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Singapore market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Key company market share/position analysis, 2025
  • 9.4. Company Profiles
    • 9.4.1. Leica Biosystems Nussloch GmbH (subsidiary of Danaher)
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Hamamatsu Photonics K.K.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Koninklijke Philips N.V.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Olympus Corporation
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. F. Hoffmann-La Roche Ltd.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Aiforia/ Aiforia Technologies PLC
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Epredia (3DHISTECH Ltd.)
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Visiopharm A/S
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Proscia Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Mindpeak GmbH
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. Akoya Biosciences, Inc. (a Quanterix company)
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. Paige AI, Inc.
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. CellaVision
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. aetherAI
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. Qritive
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
      • 9.4.15.4. Strategic initiatives
    • 9.4.16. IBEX (IBEX MEDICAL ANALYTICS)
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiatives
    • 9.4.17. Nucleai, Inc.
      • 9.4.17.1. Company overview
      • 9.4.17.2. Financial performance
      • 9.4.17.3. Product benchmarking
      • 9.4.17.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제